Project Grant R01AI183599

Award Date 12/1/24
Completion Date 11/30/29
Dollars Obligated $1.6M
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21201, USA
Similar Awards
This $1,480,500 federal Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) will fund research by The Trustees of Columbia University in the City of New York to identify and characterize the roles of non-coding RNAs in regulating drug-induced quiescence in Plasmodium falciparum, the parasite that causes malaria. The project aims to uncover novel epigenetic and epitranscriptomic mechanisms that enable...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $479,204 to the University of Maryland, Baltimore to conduct research on parasite variant surface antigens and their role in severe malaria. The research aims to identify parasite genes associated with severe disease, which could inform vaccine and drug development. Key aspects include: Sequencing variant surface antigen transcripts...
This federal Project Grant award of $375,000.00 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research into the functions of messenger ribonucleoproteins (mRNPs) in regulating mRNA metabolism and translation in the malaria parasite Plasmodium falciparum. The research aims to identify molecular markers for distinct mRNP granules, determine their compositions, and characterize their...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $700,288.00 in funding to the University of South Florida to conduct research on identifying genetic factors associated with the sexual stage development of the malaria parasite Plasmodium falciparum. The project leverages a functional genomics approach using random PiggyBac mutagenesis to screen for genes...
This Project Grant award of $206,116, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of novel 4-aminoquinoline compounds as potential therapeutics against multi-drug resistant Plasmodium falciparum, the deadliest malaria parasite. The award recipient, Oregon Health & Science University (OHSU), will conduct iterative medicinal chemistry to identify compounds with...
This federal Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports a longitudinal cohort study to examine the impact of early childhood malaria prevention interventions on malaria risk in school-age children in Ghana. The study, titled "IMPACT OF EARLY CHILDHOOD MALARIA PREVENTION ON MALARIA RISK AT SCHOOL ENTRY (ERASE)", will evaluate the epidemiological and...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to investigate heme homeostasis mechanisms in the malaria parasite Plasmodium falciparum. The $153,056 award will fund a 1.5-year research project at The Washington University to identify and characterize heme-binding proteins that enable the parasite to maintain appropriate heme levels during blood stage replication....
This $147,656 federal Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to understand the role of transmembrane proteins in the cell division process of the malaria parasite Plasmodium falciparum. The award, effective January 22, 2025 through October 31, 2027, will enable the integration of biochemical and super-resolution microscopy approaches to decipher...
This $791,864 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) is funding research at the University of California, Riverside (UC Riverside) to decipher the role of non-coding RNAs in gene regulation for the human malaria parasite Plasmodium falciparum. The project aims to elucidate the importance of long non-coding RNAs (lncRNAs) in parasite development, virulence, and...
The federal Project Grant award of $459,131, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research (CFDA 93.855) program, supports research to identify essential functions of the mitochondrion in malaria parasites. The goal is to uncover novel drug targets within the parasite mitochondrion that could lead to the development of new antimalarial treatments effective against both symptomatic and transmission stages of malaria...

This federal Project Grant award, funded by the National Institutes of Health (NIH) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop a genomic surveillance approach for monitoring the emergence of artemisinin resistance in Plasmodium falciparum malaria parasites in Africa. The total funding award is $1,553,810.00 and the project period runs from December 1, 2024 to November 30, 2029.

The key objectives of this research project are to: 1) identify parasite genetic loci under selection in four African endemic countries over time following the implementation of artemisinin-based combination therapies (ACTs); 2) validate the functional profiles associated with artemisinin resistance using genetic crosses and transcriptomic analyses; and 3) assess the population-level and within-host dynamics of selected alleles in Mali to inform future genomic surveillance strategies. The project will be conducted by the University of Maryland, Baltimore, with a sub-award to the University of Sciences, Techniques and Technologies of Bamako in Mali to support in-country research activities.

The findings from this comprehensive genomic surveillance approach are expected to enable earlier detection of emerging artemisinin resistance in Africa, before it manifests clinically, and provide critical insights to guide the design of future resistance monitoring efforts.

Generated 7/8/25, 1:34 PM